Bris­tol My­ers bets $100M on Avid­i­ty's RNA ther­a­pies for car­dio­vas­cu­lar dis­eases

Bris­tol My­ers Squibb is fur­ther tap­ping in­to Avid­i­ty Bio­sciences for $100 mil­lion up­front to work on up to five car­dio­vas­cu­lar tar­gets.

The Big Phar­ma wants more of the San Diego biotech’s RNA ther­a­peu­tic work for its car­dio­vas­cu­lar pipeline and is will­ing to dole out $60 mil­lion in cash, buy $40 mil­lion of Avid­i­ty stock at a hefty pre­mi­um, dish out $1.35 bil­lion for R&D mile­stones, plus an­oth­er $825 mil­lion in com­mer­cial biobucks, the drug­mak­ers said Tues­day morn­ing. Tack on roy­al­ties up to low dou­ble-dig­its for good mea­sure.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER